Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell 2Subcutaneous panniculitis-like T-cell lymphoma 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Specimen Handling 7Biopsy 7Magnetic Resonance Spectroscopy 6duvelisib 3X-Rays 3sodium-iodide symporter 2cemiplimab 2Photons 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immunoglobulin G 2Etoposide 2Disulfides 2Cyclophosphamide 2Azacitidine 210-propargyl-10-deazaaminopterin 2tazemetostat 1talimogene laherparepvec 1ruxolitinib 1pembrolizumab 1carmustine, poliferprosan 20 drug combination 1belinostat 1Whole-Body Irradiation 1Vincristine 1Stem Cell Transplantation 1Standard of Care 1Spinal Puncture 1Prednisone 1Practice Guidelines as Topic 1Pharmacogenomic Variants 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × 10-propargyl-10-deazaaminopterin × 30 days × Clear all
NCT03598998 2026-05-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

City of Hope Medical Center

Phase 1/2 Active not recruiting
13 enrolled 12 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT07225985 2026-05-11

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡